NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Eucrates
Biomedical Acquisition Corp. (the "Company"), a special purpose
acquisition company formed for the purpose of effecting a merger,
share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses, today
announced that holders of the units sold in the Company's initial
public offering of 10,000,000 units, may elect to separately trade
the ordinary shares and redeemable warrants included in the units.
Those units not separated will continue to trade on The Nasdaq
Capital Market ("Nasdaq") under the symbol "EUCRU," and the
ordinary shares and redeemable warrants that are separated will
trade on the Nasdaq under the symbols "EUCR" and "EUCRW,"
respectively. No fractional warrants will be issued upon separation
of the units and only whole warrants will trade. Holders of units
will need to have their brokers contact Continental Stock Transfer
& Trust Company, the Company's transfer agent, in order to
separate the units into ordinary shares and redeemable
warrants.
![* Image from an early copy edition of Euclid’s Elements by the 13th Century scholar and polymath Nasir al-Din al-Tusi (D.1274). * Image from an early copy edition of Euclid’s Elements by the 13th Century scholar and polymath Nasir al-Din al-Tusi (D.1274).](https://mma.prnewswire.com/media/1385538/Eucrates_Logo.jpg)
The units were initially offered by the Company in an
underwritten offering. Stifel and H.C. Wainwright & Co. acted
as joint book-running managers for the offering.
A registration statement relating to the units and the
underlying securities was declared effective by the Securities and
Exchange Commission (the "SEC") on October
23, 2020.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Eucrates Biomedical Acquisition Corp.
Eucrates
Biomedical Acquisition Corp. is a special purpose acquisition
company formed for the purpose of effecting a merger, share
exchange, asset acquisition, share purchase, reorganization or
similar business combination with one or more businesses. While the
Company may pursue an initial business combination target in any
business or industry, it intends to focus on the biomedical and
healthcare industry. The Company intends to target North American
and European healthcare companies with the potential to drive
transformational change through the convergence of biomedicine and
data science. "Eucrates" is a portmanteau, formed by combining
Euclid (the Father of Geometry) and Hippocrates (the Father of
Medicine).
Cautionary Note Concerning Forward-Looking
Statements
This press release contains statements that
constitute "forward-looking statements." Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company, including those set forth in the Risk
Factors section of the Company's registration statement and
prospectus for the Company's initial public offering filed with the
Securities and Exchange Commission (the "SEC"). Copies are
available on the SEC's website, www.sec.gov. The Company undertakes
no obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
* Image in headline from an early copy edition of Euclid's
Elements by the 13th Century scholar and polymath Nasir al-Din al-Tusi (D.1274).
View original content to download
multimedia:http://www.prnewswire.com/news-releases/eucrates-biomedical-acquisition-corp-announces-the-separate-trading-of-its-ordinary-shares-and-redeemable-warrants-301192430.html
SOURCE Eucrates Biomedical Acquisition Corp.